| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 13,649,638 | |||
| Accounts receivable, non-trade | 1,758 | |||
| Restricted cash | 78,564 | |||
| Prepaid insurance expense | 222,319 | |||
| Total current assets | 13,952,279 | |||
| Property and equipment, net | 2,573 | |||
| Intangible assets, net | 4,639,108 | |||
| Operating lease right-of-use assets | 75,219 | |||
| Goodwill | 8,674,734 | |||
| Total assets | 27,343,913 | |||
| Accounts payable | 1,370,728 | |||
| Accrued expenses and other current liabilities | 3,668,338 | |||
| Operating lease liability | 85,210 | |||
| Total current liabilities | 5,124,276 | |||
| Contingent consideration | 1,156,912 | |||
| Deferred tax liability | 460,320 | |||
| Accompanying warrants liability | 8,092,218 | |||
| Total liabilities | 14,833,726 | |||
| Common stock, 0.00001 par value, 2,357,613 and 1,978,460 shares issued and outstanding at september 30, 2025 and june 30, 2025, respectively | 23 | |||
| Additional paid-in capital, net of subscription receivable | 203,559,216 | |||
| Accumulated other comprehensive loss, net of tax | -2,795,845 | |||
| Accumulated deficit | -188,253,207 | |||
| Total shareholders equity | 12,510,187 | |||
| Total liabilities and shareholders equity | 27,343,913 | |||
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)